Subcutaneous peri-incisional injections of onabotulinum toxinA may represent an effective approach for alleviating chronic head pain associated with lateral skull base surgery and temporoparietal fascial flap harvest.
The injection of onabotulinumtoxinA toward the sphenopalatine ganglion in patients with trigeminal neuralgia may not reduce the number of attacks.
Preliminary findings showed the decrease in botulinum toxin type A therapeutic effect over time warrants further study.
Long-term use of onabotulinumtoxinA for chronic migraine prophylaxis was associated with reduced headache day frequency and improved quality of life.
Although the quality of evidence is low due to variable study designs, botulinum toxin may be beneficial in the treatment of chronic tension-type headaches for specific patients with clear treatment goals.
Improvement in quality of life at 3 months was higher in the botulinum toxin group vs the placebo group.
A wearing off of responses to onabotulinumtoxinA during the first treatment cycle may be common in individuals with chronic migraine.
OnabotulinumtoxinA treatment was found to reduce the frequency of headache days in patients with chronic migraine with and without daily headaches.
OnabotulinumtoxinA treatment was found to reduce the frequency and severity of monthly headache days and to improve quality of life and disability in patients with chronic migraine with or without allodynia.
OnabotulinumtoxinA not only reduced headache frequency for patients with chronic migraines, but also showed potential for clinically reducing depression and anxiety symptoms.
